West Pharmaceutical Services (WST) Liabilities and Shareholders Equity (2009 - 2026)

West Pharmaceutical Services (WST) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 3.13% year-over-year to $4.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.6 billion (up 11.23% YoY) and the FY2025 annual result came in at $4.3 billion, up 17.2% from the prior year.
• Liabilities and Shareholders Equity fell to $4.1 billion in Q2 2026 per WST's latest filing, from $4.1 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for WST reached as high as $4.3 billion in Q4 2025 and fell as low as $3.3 billion in Q1 2022.
• A 5-year average of $3.7 billion and a median of $3.7 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 20.26% — and 2024, when it fell 4.91%.
• Year by year, Liabilities and Shareholders Equity stood at $3.6 billion in 2022, then advanced by 5.88% to $3.8 billion in 2023, then decreased by 4.86% to $3.6 billion in 2024, then grew by 17.2% to $4.3 billion in 2025, then declined by 4.53% to $4.1 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.1 billion, $4.1 billion, and $4.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.